ArticleDermatology online journal2026
Mindful approaches: Association between atopic dermatitis and autism spectrum disorder and use of visual storyboards.
Article in Dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study compared the prevalence of atopic dermatitis (AD) in pediatric patients with autism spectrum disorder (ASD) versus controls and explored approaches to AD management in children with ASD. We conducted a cross-sectional analysis of the International Business Machines Explorys electronic medical records database in the United States from January 1, 2017, to December 31, 2019. The primary outcome was International Classification of Diseases-10 diagnosis of AD with asthma or allergic rhinitis, a validated algorithm for identifying true AD cases. Logistic regression compared crude prevalence and assessed associations independent of potential confounders. AD prevalence was 5.0% among patients with ASD and 3.6% among controls (crude odds ratio (OR), 1.41; 95% CI, 1.23-1.61). After adjustment for demographics and healthcare visit frequency, the OR attenuated to 1.15 (95% CI, 1.01-1.32;
Indexed as
Identifiers
42246339What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.